Biotech bulls see a bright year ahead for the sector thanks to a range of catalysts outside of COVID. As today’s article explains, “Among the most closely tracked catalysts are the potential approval of Biogen Inc.’s experimental drug for Alzheimer’s disease, expectations for a rebound in deal-making activity, and innovations from gene therapy updates to next-generation cancer technologies.” For more on what has money managers bullish on biotech in 2021, CLICK HERE.
